Valaciclovir
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Valaciclovir: From Herpesvirus Infection to Rheumatoid Arthritis
One-Sentence Summary
Valaciclovir is an oral antiviral prodrug of acyclovir, and it is marketed in Singapore under three registrations. The TxGNN model predicts it may be effective for rheumatoid arthritis, but no clinical trials are registered and the 5 publications retrieved are case reports and cohort studies. These describe herpes infections occurring in RA patients on immunosuppressants and do not test valaciclovir as a treatment for RA.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the Singapore licence records (approved indication text is empty) |
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 98.95% |
| Evidence Level | L4 (assigned in the compiled data; the literature found is only case reports and a cohort study, so it is not direct evidence of efficacy) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Valaciclovir is generally known as a prodrug of acyclovir, which inhibits herpesvirus DNA polymerase. It is used against herpes simplex and herpes zoster infections.
There is no direct mechanistic rationale for valaciclovir treating rheumatoid arthritis. RA is an autoimmune joint disease, and valaciclovir has no known anti-inflammatory or immunomodulatory action against it. The retrieved literature reports herpes zoster or herpes simplex infections in RA patients receiving tofacitinib, infliximab or methotrexate. This supports using valaciclovir for infectious complications in RA patients, not for RA itself.
The high TxGNN score most likely reflects network proximity or co-occurrence in the knowledge graph rather than a true therapeutic effect. The prediction should be treated as a weak hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24660085 | 2014 | Case report | Case Reports in Rheumatology | Ramsay Hunt syndrome (varicella zoster reactivation) in an RA patient after infliximab, treated with valaciclovir and hydrocortisone, with full recovery at 6 months |
| 35236687 | 2022 | Case report | BMJ Case Reports | Herpes zoster meningitis in an RA patient taking tofacitinib; the drug was discontinued and the infection treated |
| 14600805 | 2003 | Case report | Intensive Care Medicine | Disseminated tuberculosis, aspergillosis and cutaneous herpes simplex in an RA patient on infliximab and methotrexate |
| 10220730 | 1999 | Case report | Klinische Monatsblätter für Augenheilkunde | Bilateral neuroretinitis with zoster infection, with a suspected autoimmune inflammatory reaction |
| 23211260 | 2012 | Cohort | British Journal of General Practice | Antiviral prescribing patterns after herpes zoster in general practice |
None of these papers evaluates valaciclovir as a treatment for RA.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN08229P | VALTREX TABLET 500 mg | Film-coated tablet | Not specified in the licence records |
| SIN14207P | Vaciclor Tablet 500 mg | Film-coated tablet | Not specified in the licence records |
| SIN14878P | VALOVIR 500 VALACYCLOVIR TABLETS 500 mg | Tablet | Not specified in the licence records |
All three are valid single-ingredient oral products.
Safety Considerations
- Drug Interactions: 100 interactions were found in the DDInter database. The main ones are listed below.
- Moderate: mesalazine, balsalazide, olsalazine, sulfasalazine, paromomycin, neomycin, streptomycin, trospium
- Minor: cimetidine
- Level not classified: calcitriol, pantoprazole, omeprazole, lansoprazole, metformin, glimepiride, doxycycline, clotrimazole, morphine, atropine, acarbose
- Renal consideration: Valaciclovir is cleared by the kidney, so dose adjustment is needed in renal impairment. This is general pharmacological knowledge, not taken from the licence data.
Warnings and contraindications from the package insert were not available. Please refer to the package insert for these.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials, and the literature describes treating herpes infections in RA patients rather than treating RA. No plausible mechanism links valaciclovir to RA.
To proceed, the following is needed:
- Detailed mechanism of action data (MOA)
- Package insert warnings and contraindications from the HSA, and the approved indications for the Singapore licences
- Any preclinical or clinical evidence that valaciclovir affects RA disease activity (for example, a viral-trigger hypothesis such as EBV)
- A clear separation between use for infectious complications and a true new-indication claim
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.